Addex Therapeutics CEO awarded 18.9M stock options
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Addex Therapeutics Ltd. (ADXN) Chief Executive Officer Timothy Mark Dyer received an award of 18,857,075 stock options on November 11, 2026. Each option grants the right to purchase one ADXN share at a reported exercise price of $0.026 per share. The options vest in equal monthly installments over four years beginning at the exercisable date and expire November 10, 2036. His reported position after the award was 22,226,871 shares underlying options.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock-option (Right to Buy) F2, F1 | 18,857,075 | $0.00 | $0.00 |
Footnotes (2)
- F1. The stock-options vest on equal monthly installments over a 4-year period beginning at the exercisable date. Each stock-option grants to right to purchase one ADXN share listed on SIX Swiss Exchange.
- F2. The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $ 1.1995 per CHF 1.00 as of November 11, 2026.
Key Figures
Key Terms
exercise price financial
vest technical
exercisable date technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many ADXN options did Timothy Mark Dyer receive, and at what exercise price?
When do Timothy Mark Dyer’s ADXN options vest and expire?
AI-generated analysis. How Rhea-AI works. Not financial advice.